EBS

SEC source: 0001140361-18-011288 · doc1.xml · nonDerivative · entry 3

Kramer Robert · CIK 0001380956 · EVP, Administration and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,151

F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

SEC source: 0001140361-18-011288 · doc1.xml · nonDerivative · entry 2

Kramer Robert · CIK 0001380956 · EVP, Administration and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,929

F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period.

SEC source: 0001140361-18-011288 · doc1.xml · nonDerivative · entry 1

Kramer Robert · CIK 0001380956 · EVP, Administration and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,012

F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001140361-18-011296 · doc1.xml · derivative · entry 3

SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,253

Underlying: Common Stock · 21,253 shares

Expires 2025-02-26

F4 · derivative.exercise_date: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021.

SEC source: 0001140361-18-011296 · doc1.xml · nonDerivative · entry 2

SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,440

F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period.

SEC source: 0001140361-18-011296 · doc1.xml · nonDerivative · entry 1

SARAN ATUL · CIK 0001591070 · EVP, Corp Dev, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,127

F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001140361-18-011285 · doc1.xml · derivative · entry 6

Havey Adam · CIK 0001514588 · EVP, Business Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,145

Underlying: Common Stock · 20,145 shares

Expires 2025-02-26

F4 · derivative.exercise_date: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021.

SEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 3

Havey Adam · CIK 0001514588 · EVP, Business Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,709

F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

SEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 2

Havey Adam · CIK 0001514588 · EVP, Business Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,118

F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period.

SEC source: 0001140361-18-011285 · doc1.xml · nonDerivative · entry 1

Havey Adam · CIK 0001514588 · EVP, Business Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,082

F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001140361-18-011280 · doc1.xml · derivative · entry 6

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,485

Underlying: Common Stock · 53,485 shares

Expires 2025-02-26

F4 · derivative.exercise_date: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021.

SEC source: 0001140361-18-011280 · doc1.xml · nonDerivative · entry 3

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227,552

F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

SEC source: 0001140361-18-011280 · doc1.xml · nonDerivative · entry 2

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,876

F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period.

SEC source: 0001140361-18-011280 · doc1.xml · nonDerivative · entry 1

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,505

F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.

F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001140361-18-003133 · doc1.xml · nonDerivative · entry 3

Hauer Jerome M · CIK 0001294935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,068

F1 · price: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Hauer.

SEC source: 0001140361-18-003133 · doc1.xml · derivative · entry 4

Hauer Jerome M · CIK 0001294935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,152 shares

Expires 2022-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Consists of an option granted on January 22, 2015 under the company's stock incentive plan as amended and restated.

F4 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-18-003133 · doc1.xml · nonDerivative · entry 2

Hauer Jerome M · CIK 0001294935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,645

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.25 to $51.25, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F1 · price: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Hauer.

SEC source: 0001140361-18-003133 · doc1.xml · nonDerivative · entry 1

Hauer Jerome M · CIK 0001294935 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,797

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Hauer.

SEC source: 0001140361-18-000849 · doc1.xml · derivative · entry 4

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,906 shares

Expires 2019-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Consists of an option granted under the company's stock incentive plan as amended and restated.

F5 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-18-000849 · doc1.xml · nonDerivative · entry 2

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,134

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.62 to $48.13, inclusive.

SEC source: 0001140361-18-000849 · doc1.xml · nonDerivative · entry 1

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,040

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.

SEC source: 0001140361-17-046253 · doc1.xml · derivative · entry 4

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,906

Underlying: Common Stock · 20,000 shares

Expires 2019-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: Consists of an option granted under the company's stock incentive plan as amended and restated.

F5 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-046253 · doc1.xml · nonDerivative · entry 2

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,134

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $46.24, inclusive.

SEC source: 0001140361-17-046253 · doc1.xml · nonDerivative · entry 1

Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 224,134

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.

SEC source: 0001140361-17-045941 · doc1.xml · derivative · entry 3

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,681 shares

Expires 2019-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated.

F4 · derivative.exercise_date: The option grant is fully vested.

SEC source: 0001140361-17-045941 · doc1.xml · nonDerivative · entry 2

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,410

F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.17, inclusive.

SEC source: 0001140361-17-045941 · doc1.xml · nonDerivative · entry 1

Richard Ronald · CIK 0001380177 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,091

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Richard.

SEC source: 0001140361-17-045556 · doc1.xml · nonDerivative · entry 1

Harsanyi Zsolt · CIK 0001380184 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,077

F1 · security: Consists of vested restricted stock units granted under the Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended and restated.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.35 to $42.59, inclusive.

SEC source: 0000899243-17-027619 · doc4.xml · derivative · entry 8

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,983 shares

Expires 2018-03-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014.

SEC source: 0000899243-17-027619 · doc4.xml · nonDerivative · entry 4

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,530,216

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

F3 · price: The selling price of $42.08 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $41.78 to $42.38, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-17-027619 · doc4.xml · nonDerivative · entry 3

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,558,199

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

SEC source: 0000899243-17-027619 · doc4.xml · derivative · entry 7

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,983

Underlying: Common Stock · 20,000 shares

Expires 2018-03-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014.

SEC source: 0000899243-17-027619 · doc4.xml · nonDerivative · entry 2

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,530,216

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

F2 · price: The selling price of $41.59 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $41.03 to $41.82, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-17-027619 · doc4.xml · nonDerivative · entry 1

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,550,216

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

SEC source: 0000899243-17-026353 · doc4.xml · nonDerivative · entry 2

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,490,216

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.81 to $40.55.

SEC source: 0000899243-17-026845 · doc4a.xml · derivative · entry 8

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,983

Underlying: Common Stock · 20,000 shares

Expires 2018-03-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014.

SEC source: 0000899243-17-026845 · doc4a.xml · nonDerivative · entry 4

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,530,216

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

F3 · price: The selling price of $40.05 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $39.81 to $40.55, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-17-026845 · doc4a.xml · nonDerivative · entry 3

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,550,216

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

SEC source: 0000899243-17-026353 · doc4.xml · nonDerivative · entry 1

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,510,216

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.26 to $40.98.

SEC source: 0000899243-17-026845 · doc4a.xml · derivative · entry 7

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,983

Underlying: Common Stock · 20,000 shares

Expires 2018-03-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The options vested in three equal installments on March 14, 2012, March 14, 2013 and March 14, 2014.

SEC source: 0000899243-17-026845 · doc4a.xml · nonDerivative · entry 2

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,530,216

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

F2 · price: The selling price of $40.69 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $40.26 to $40.98, inclusive. Mr. El-Hibri undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-17-026845 · doc4a.xml · nonDerivative · entry 1

El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,550,216

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on February 28, 2017 that is intended to comply with Rule 10b5-1(c) under the Exchange Act.

SEC source: 0001140361-17-042137 · doc1.xml · nonDerivative · entry 2

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,743

F1 · security: Consists of restricted stock units granted under the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.

F2 · shares: The restricted stock units vest in three equal annual tranches beginning in November 2017.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.84 to $40.85, inclusive.

SEC source: 0001140361-17-042137 · doc1.xml · nonDerivative · entry 1

Zoon Kathryn C · CIK 0001685720 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,114

F1 · security: Consists of restricted stock units granted under the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.

F2 · shares: The restricted stock units vest in three equal annual tranches beginning in November 2017.

F3 · shares: The transactions reported in this row were effected pursuant to a Rule 10b5-1 plan adopted by Dr. Zoon.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.25, inclusive.

SEC source: 0001140361-17-041866 · doc1.xml · derivative · entry 6

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,305 shares

Expires 2021-05-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated.

F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-041866 · doc1.xml · derivative · entry 5

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,946 shares

Expires 2020-07-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Consists of an option granted under the company's stock incentive plan as amended and restated.

F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant.

SEC source: 0001140361-17-041866 · doc1.xml · nonDerivative · entry 4

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,377

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.45, inclusive.

SEC source: 0001140361-17-041866 · doc1.xml · nonDerivative · entry 3

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-17-041866 · doc1.xml · nonDerivative · entry 2

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,377

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.45, inclusive.

SEC source: 0001140361-17-041866 · doc1.xml · nonDerivative · entry 1

JOULWAN GEORGE A · CIK 0001222197 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,323

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.